ESPR
$39.14
Esperion Theraptc
($.22)
(.56%)
ESPR
Earnings Whisper ®
N/A
3rd Quarter September 2019
Consensus:  ($2.01)
Revenue:  $0.93 Mil
Thursday
Oct 31
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ESPR reports earnings?
Beat
Meet
Miss

Where is ESPR's stock price going from here?
Up
Flat
Down
Stock chart of ESPR
Analysts
Summary of analysts' recommendations for ESPR
Score
Grade
Pivots
Resistance
$41.10
$40.44
$39.79

$39.13

Support
$38.48
$37.82
$37.17
Tweet
Growth
Description
Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan.
Peers
Regeneron PharmaceuticalsCelgeneInterCeptVertex PharmaceuticalsBioMarin PharmaceuticalEndo International plcJohnson & JohnsonMylanZoetisPerrigo